Literature DB >> 22300026

α7-Nicotinic receptors and cognition.

Edward D Levin1.   

Abstract

Nicotinic α7 receptors have been shown in a variety of studies with animal models to play important roles in diverse components of cognitive function, including learning, memory and attention. Mice with α7 receptor knockouts show impairments in memory. Selective α7 agonists significantly improve learning, memory and attention. α7 receptors in limbic structures such as the hippocampus and amygdala have been demonstrated to play critical roles in memory. Blockade of α7 receptors in these areas cause memory impairments. In the brains of people with schizophrenia α7 receptors are impaired. This may be related to pronounced cognitive impairments seen with schizophrenia. There has been a major effort to develop α7 nicotinic agonists for helping to reverse cognitive impairment. These receptors are a promising target for development of therapeutic treatments for a variety of diseases of cognitive impairment including Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300026     DOI: 10.2174/138945012800398937

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  29 in total

1.  The α7 nicotinic acetylcholine receptors regulate hippocampal adult-neurogenesis in a sexually dimorphic fashion.

Authors:  Simone L Otto; Jerrel L Yakel
Journal:  Brain Struct Funct       Date:  2018-12-04       Impact factor: 3.270

2.  Neuroprotective evidence of alpha-lipoic acid and desvenlafaxine on memory deficit in a neuroendocrine model of depression.

Authors:  Caren Nádia Soares de Sousa; Lucas Nascimento Meneses; Germana Silva Vasconcelos; Ingridy da Silva Medeiros; Márcia Calheiros Chaves Silva; Fayçal Mouaffak; Oussama Kebir; Cláudio Manuel Gonçalves da Silva Leite; Manoel Cláudio Azevedo Patrocinio; Danielle Macedo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-07       Impact factor: 3.000

3.  Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex.

Authors:  Yang Yang; Constantinos D Paspalas; Lu E Jin; Marina R Picciotto; Amy F T Arnsten; Min Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

4.  α7-Containing nicotinic acetylcholine receptors on interneurons of the basolateral amygdala and their role in the regulation of the network excitability.

Authors:  Volodymyr I Pidoplichko; Eric M Prager; Vassiliki Aroniadou-Anderjaska; Maria F M Braga
Journal:  J Neurophysiol       Date:  2013-09-04       Impact factor: 2.714

Review 5.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

Review 6.  Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.

Authors:  Alan S Lewis; Gerrit I van Schalkwyk; Michael H Bloch
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-01-05       Impact factor: 5.067

7.  Opportunities and challenges in modeling human brain disorders in transgenic primates.

Authors:  Charles G Jennings; Rogier Landman; Yang Zhou; Jitendra Sharma; Julia Hyman; J Anthony Movshon; Zilong Qiu; Angela C Roberts; Anna Wang Roe; Xiaoqin Wang; Huihui Zhou; Liping Wang; Feng Zhang; Robert Desimone; Guoping Feng
Journal:  Nat Neurosci       Date:  2016-08-26       Impact factor: 24.884

8.  Chronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia.

Authors:  B Hambsch; H Keyworth; J Lind; D M Otte; I Racz; I Kitchen; A Bailey; A Zimmer
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.

Authors:  Danhui Zhang; Matthew McGregor; Tanuja Bordia; Xiomara A Perez; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2015-11-17       Impact factor: 10.338

Review 10.  Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders.

Authors:  Amy F T Arnsten; Min Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.